4D Molecular Therapeutics to present at two major healthcare investor conferences in May 2026

4D Molecular Therapeutics, a late-stage biotech company, announced it will present and hold one-on-one meetings at the BofA Securities Healthcare Conference on May 13 and the RBC Global Healthcare Conference on May 19, 2026. The company is advancing treatments for retinal diseases and cystic fibrosis, with its lead product 4D-150 in Phase 3 trials for wet age-related macular degeneration. These presentations aim to update investors on progress and future milestones. Archived webcasts will be available for one year on the company's investor website.